Allos Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of anti-cancer therapeutics. As of December 31, 2011, the Company focused on the development and commercialization of FOLOTYN (pralatrexate injection). FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. FOLOTYN targets the inhibition of dihydrofolate reductase (DHFR), an enzyme critical in the folate pathway, thereby interfering with deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) synthesis and triggering cancer cell death. FOLOTYN can be delivered as a single agent, for which the Company has approval for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), and can be used in combination therapy regimens. On September 5, 2012, Spectrum Pharmaceuticals, Inc. acquired Allos Therapeutics, Inc.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:ALTH
- CUSIP: N/A
- Web: N/A
- Trailing P/E Ratio:
- P/E Growth:
Frequently Asked Questions for Allos Therapeutics (NASDAQ:ALTH)
What is Allos Therapeutics' stock symbol?
Allos Therapeutics trades on the NASDAQ under the ticker symbol "ALTH."
Who are some of Allos Therapeutics' key competitors?
Some companies that are related to Allos Therapeutics include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), Valeant Pharmaceuticals Intl (VRX), NMC Health PLC (NMC), Health Net (HNT), ConvaTec Group PLC (CTEC), Mediclinic International PLC (MDC), Patheon NV (PTHN), Catalent (CTLT), PRA Health Sciences (PRAH), Puma Biotechnology (PBYI), WuXi PharmaTech (Cayman) (WX) and Cotiviti Holdings (COTV).
How do I buy Allos Therapeutics stock?
MarketBeat Community Rating for Allos Therapeutics (NASDAQ ALTH)MarketBeat's community ratings are surveys of what our community members think about Allos Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Shares of Allos Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
Consensus Ratings for Allos Therapeutics (NASDAQ:ALTH) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Allos Therapeutics (NASDAQ:ALTH)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Allos Therapeutics (NASDAQ:ALTH)Earnings History by Quarter for Allos Therapeutics (NASDAQ ALTH)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Allos Therapeutics (NASDAQ:ALTH)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Allos Therapeutics (NASDAQ:ALTH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Allos Therapeutics (NASDAQ:ALTH)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Allos Therapeutics (NASDAQ:ALTH)
Latest Headlines for Allos Therapeutics (NASDAQ:ALTH)
No headlines for this company have been tracked by MarketBeat.com
Allos Therapeutics (ALTH) Chart for Wednesday, September, 20, 2017